Our Ambition

Become a key player in the gut-liver axis field

Develop our proprietary LBP Portfolio

Develop a portfolio of breakthrough Live Biotherapeutic Products (LBPs) modulating the gut-liver axis

Explore the Coriobacteria Universe

Enter the unexplored universe of coriobacteria, starting with our first project ADC-001 in NAFLD / NASH

Set-up a unique discovery Platform

Set up our NovoDiscovery platform aggregating cutting-edge technologies that could revolutionize ex vivo research

"The relationships between the host and its microbiota are still poorly appreciated, notably in liver diseases. NovoBiome will open up new and highly impactful perspectives in terms of diagnosis, as well as preventive and therapeutic strategies targeting liver diseases along with the implementation an outstanding platform that mimics human intestinal physiology."